These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20957143)

  • 1. Lucentis using Visudyne study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration.
    Chen E; Brown DM; Wong TP; Benz MS; Kegley E; Cox J; Fish RH; Kim RY
    Clin Ophthalmol; 2010 Oct; 4():1073-9. PubMed ID: 20957143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial.
    Lim TH; Lai TYY; Takahashi K; Wong TY; Chen LJ; Ruamviboonsuk P; Tan CS; Lee WK; Cheung CMG; Ngah NF; Patalauskaite R; Margaron P; Koh A;
    JAMA Ophthalmol; 2020 Sep; 138(9):935-942. PubMed ID: 32672800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.
    Koh A; Lai TYY; Takahashi K; Wong TY; Chen LJ; Ruamviboonsuk P; Tan CS; Feller C; Margaron P; Lim TH; Lee WK;
    JAMA Ophthalmol; 2017 Nov; 135(11):1206-1213. PubMed ID: 28983556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration.
    Vallance JH; Johnson B; Majid MA; Banerjee S; Mandal K; Bailey CC
    Eye (Lond); 2010 Oct; 24(10):1561-7. PubMed ID: 20577273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration.
    Sivaprasad S; Patra S; DaCosta J; Adewoyin T; Shona O; Pearce E; Chong NV
    Ophthalmologica; 2011; 225(4):200-6. PubMed ID: 21293163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration.
    Williams PD; Callanan D; Solley W; Avery RL; Pieramici DJ; Aaberg T
    Clin Ophthalmol; 2012; 6():1519-25. PubMed ID: 23055673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
    Spielberg L; Leys A
    Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of photodynamic therapy, ranibizumab/bevacizumab or combination in the treatment of myopic choroidal neovascularisation: a 9-year-study from a single centre.
    Rishi P; Rishi E; Bhende M; Agarwal V; Vyas CH; Valiveti M; Bhende P; Rao C; Susvar P; Sen P; Raman R; Khetan V; Murali V; Ratra D; Sharma T
    Br J Ophthalmol; 2016 Oct; 100(10):1337-40. PubMed ID: 26792945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: a randomized clinical trial.
    Maberley D;
    Ophthalmology; 2009 Nov; 116(11):2149-57.e1. PubMed ID: 19748675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing efficacy of reduced-fluence and standard-fluence photodynamic therapy in the treatment of polypoidal choroidal vasculopathy.
    Ngo WK; Chee WK; Tan CS; Lim TH
    BMC Ophthalmol; 2020 Apr; 20(1):150. PubMed ID: 32293353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study.
    Kaiser PK; Boyer DS; Cruess AF; Slakter JS; Pilz S; Weisberger A;
    Ophthalmology; 2012 May; 119(5):1001-10. PubMed ID: 22444829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of verteporfin photodynamic therapy and ranibizumab: effects on retinal anatomy, choroidal perfusion and visual function in the protect study.
    Kiss CG; Simader C; Michels S; Schmidt-Erfurth U
    Br J Ophthalmol; 2008 Dec; 92(12):1620-7. PubMed ID: 19029163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
    Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
    Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey.
    Husain D; Kim I; Gauthier D; Lane AM; Tsilimbaris MK; Ezra E; Connolly EJ; Michaud N; Gragoudas ES; O'Neill CA; Beyer JC; Miller JW
    Arch Ophthalmol; 2005 Apr; 123(4):509-16. PubMed ID: 15824225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal ranibizumab combined with verteporfin photodynamic therapy for treating polypoidal choroidal vasculopathy.
    Lee YH; Lee EK; Shin KS; Lee KM; Kim JY
    Retina; 2011; 31(7):1287-93. PubMed ID: 21386762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination treatment of photodynamic therapy with verteporfin and intravitreal ranibizumab in patients with retinal angiomatous proliferation.
    Seidel G; Werner C; Weger M; Steinbrugger I; Haas A
    Acta Ophthalmol; 2013 Sep; 91(6):e482-5. PubMed ID: 23786546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degeneration.
    Krebs I; Vécsei Marlovits V; Bodenstorfer J; Glittenberg C; Ansari Shahrezaei S; Ristl R; Binder S
    Acta Ophthalmol; 2013 May; 91(3):e178-83. PubMed ID: 23241227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.
    Koh A; Lee WK; Chen LJ; Chen SJ; Hashad Y; Kim H; Lai TY; Pilz S; Ruamviboonsuk P; Tokaji E; Weisberger A; Lim TH
    Retina; 2012 Sep; 32(8):1453-64. PubMed ID: 22426346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results.
    Larsen M; Schmidt-Erfurth U; Lanzetta P; Wolf S; Simader C; Tokaji E; Pilz S; Weisberger A;
    Ophthalmology; 2012 May; 119(5):992-1000. PubMed ID: 22424834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy.
    Ricci F; Calabrese A; Regine F; Missiroli F; Ciardella AP
    Retina; 2012 Jul; 32(7):1280-8. PubMed ID: 22218148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.